The University of Chicago Header Logo

Connection

Ralph Weichselbaum to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Ralph Weichselbaum has written about Treatment Outcome.
Ralph Weichselbaum
Connection Strength
0.613
Treatment Outcome
  1. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.062
  2. Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One. 2014; 9(4):e94456.
    View in: PubMed
    Score: 0.040
  3. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.039
  4. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013 Apr 10; 31(11):1384-90.
    View in: PubMed
    Score: 0.037
  5. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
    View in: PubMed
    Score: 0.030
  6. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007 Oct 15; 13(20):6217-23.
    View in: PubMed
    Score: 0.025
  7. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
    View in: PubMed
    Score: 0.021
  8. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004 Sep 01; 10(17):5747-53.
    View in: PubMed
    Score: 0.020
  9. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.016
  10. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol. 2020; 11:580335.
    View in: PubMed
    Score: 0.016
  11. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.015
  12. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.014
  13. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
    View in: PubMed
    Score: 0.014
  14. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.013
  15. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.013
  16. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.
    View in: PubMed
    Score: 0.013
  17. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.012
  18. From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. Clin Cancer Res. 2016 Jan 01; 22(1):20-5.
    View in: PubMed
    Score: 0.011
  19. Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis. J Thorac Oncol. 2015 Feb; 10(2):264-71.
    View in: PubMed
    Score: 0.011
  20. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):344-50.
    View in: PubMed
    Score: 0.011
  21. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
    View in: PubMed
    Score: 0.010
  22. Effect of postradiotherapy neck dissection on nonregional disease sites. JAMA Otolaryngol Head Neck Surg. 2014 Jan; 140(1):12-21.
    View in: PubMed
    Score: 0.010
  23. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.010
  24. Racial parities in outcomes after radiotherapy for head and neck cancer. Cancer. 2014 Jan 15; 120(2):244-52.
    View in: PubMed
    Score: 0.010
  25. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013 Jun; 12(3):217-24.
    View in: PubMed
    Score: 0.009
  26. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.009
  27. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.009
  28. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 2012; 7(1):e29653.
    View in: PubMed
    Score: 0.008
  29. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
    View in: PubMed
    Score: 0.008
  30. Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
    View in: PubMed
    Score: 0.008
  31. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
    View in: PubMed
    Score: 0.008
  32. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
    View in: PubMed
    Score: 0.007
  33. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.007
  34. Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med. 2009 Aug; 62(2):348-56.
    View in: PubMed
    Score: 0.007
  35. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21.
    View in: PubMed
    Score: 0.006
  36. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.005
  37. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
    View in: PubMed
    Score: 0.005
  38. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.005
  39. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
    View in: PubMed
    Score: 0.004
  40. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
    View in: PubMed
    Score: 0.004
  41. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol. 2001 Mar; 12(3):343-7.
    View in: PubMed
    Score: 0.004
  42. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5.
    View in: PubMed
    Score: 0.004
  43. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
    View in: PubMed
    Score: 0.004
  44. Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol. 1997 Jun; 15(6):2329-37.
    View in: PubMed
    Score: 0.003
  45. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
    View in: PubMed
    Score: 0.003
  46. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol. 1996 Dec; 14(12):3105-11.
    View in: PubMed
    Score: 0.003
  47. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
    View in: PubMed
    Score: 0.003
  48. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993 Apr; 149(4):753-7.
    View in: PubMed
    Score: 0.002
  49. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
    View in: PubMed
    Score: 0.002
  50. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
    View in: PubMed
    Score: 0.002
  51. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.